-
BioPharma Dive – AI / Data3 months agoNovartis pays $2B to land a startup’s breast cancer drug
Acquiring a unit of privately held Synnovation Therapeutics hands Novartis a prospect that might improve on medicines that, like its own Piqray, target tumors driven to...
-
STAT News – Biotech3 months agoA conversation with the ‘godfather’ of biotech
On this week’s episode of “The Readout LOUD,” we bring you a special conversation with Stelios Papadopolous, also know as the “godfather” of biotech. He sat...
-
AI & Machine Learning in Biotechnology3 months agoAll the highlights from STAT’s Breakthrough Summit East
Good morning and happy Friday. I’m off today, but I’ll talk to you next week. Highlights from yesterday’s summit For me, the top moment from yesterday’s...
-
Fierce Biotech3 months ago
Genentech antibody fails to boost muscle in rare diseases, raising questions for obesity trial
Genentech is halting development of an antibody for two rare genetic diseases after the candidate failed to boost muscle growth, raising questions about whether the molecule...
-
STAT News – Biotech3 months agoSTAT+: Pharmalittle: We’re reading about TrumpRx expectations, a high-dose version of Wegovy, and more
And so, another working week will soon come to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal to...
-
Uncategorized3 months agoThis week in Drug Discovery (16 – 20 March)
News round-up for 16 – 20 March February by Bruno Quinney, Content Team at DDW. This week, a pioneering method is being used to make drugs for Parkinson’s disease. Elsewhere, advances have been...
-
Endpoints News3 months ago
Novo Holdings CEO discusses investments, geopolitics and China
The assets managed by Novo Holdings, the controlling shareholder of Novo Nordisk, fell by some 35% last year. But that doesn’t mean it will rein in...
-
Uncategorized3 months agoEvotec to receive $10m as kidney cancer trial launches
Evotec will receive a $10 million milestone payment as a kidney cancer trial has got underway. Bristol Myers Squibb has launched its Phase I clinical study evaluating CELMoD agent BMS-986506, a cereblon E3...
-
Endpoints News3 months ago
Novartis to pay $2B upfront to take next-gen PI3Kα inhibitor from Synnovation
Novartis has budgeted $2 billion upfront to buy a more selective PI3Kα inhibitor for breast cancer. The Swiss pharma already has Piqray with a similar target,...
-
BioPharma Dive – AI / Data3 months agoRhythm obesity drug wins broader use from FDA
Imcivree’s clearance in a type of obesity driven by brain injury could unlock an opportunity Wall Street analysts believe to be worth more than $1 billion.
Laser‑Driven Phase Contrast Enhances Cryo‑EM Resolution of Small Proteins
STAT+: Updated: Tracking RFK Jr.’s promises to remake health in America
